266 related articles for article (PubMed ID: 25495896)
1. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Makumi CW; Asgharian A; Ellis J; Shaikh S; Jimenez T; VanMeter S
Int J Neurosci; 2016; 126(1):30-8. PubMed ID: 25495896
[TBL] [Abstract][Full Text] [Related]
2. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
Hauser RA; Reichmann H; Lew M; Asgharian A; Makumi C; Shulman KJ
Int J Neurosci; 2011 May; 121(5):246-53. PubMed ID: 21244307
[TBL] [Abstract][Full Text] [Related]
3. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
4. An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Zhu R; Li J; Hu J; Cai M
Curr Med Res Opin; 2015 Apr; 31(4):723-30. PubMed ID: 25586298
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
6. A review of ropinirole prolonged release in Parkinson's disease.
Nashatizadeh MM; Lyons KE; Pahwa R
Clin Interv Aging; 2009; 4():179-86. PubMed ID: 19503779
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Li J; Cao H; Cai M; Zhu R
Parkinsonism Relat Disord; 2013 Nov; 19(11):1022-6. PubMed ID: 23932066
[TBL] [Abstract][Full Text] [Related]
8. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.
Stocchi F; Giorgi L; Hunter B; Schapira AH
Mov Disord; 2011 Jun; 26(7):1259-65. PubMed ID: 21469195
[TBL] [Abstract][Full Text] [Related]
9. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
[TBL] [Abstract][Full Text] [Related]
10. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
[TBL] [Abstract][Full Text] [Related]
11. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.
Hattori N; Hasegawa K; Sakamoto T
J Clin Pharm Ther; 2012 Oct; 37(5):571-7. PubMed ID: 22390368
[TBL] [Abstract][Full Text] [Related]
14. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
[TBL] [Abstract][Full Text] [Related]
15. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
[TBL] [Abstract][Full Text] [Related]
16. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
19. A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.
Zesiewicz TA; Chriscoe S; Jimenez T; Upward J; VanMeter S
Neurodegener Dis Manag; 2017 Feb; 7(1):49-59. PubMed ID: 28120629
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
